Avapritinib

(Ayvakit®)

Ayvakit®

Drug updated on 12/11/2024

Dosage FormTablets (oral; 25 mg, 50 mg, 100 mg, 200 mg and 300 mg)
Drug ClassKinase Inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for Gastrointestinal Stromal Tumor (GIST): the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations
  • Indicated for Advanced Systemic Mastocytosis (AdvSM): the treatment of adult patients with AdvSM
  • AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SMAHN), and mast cell leukemia (MCL)
  • Indicated for Indolent Systemic Mastocytosis (ISM): the treatment of adult patients with ISM.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of one systematic review/meta-analysis. [1]
  • The adjusted hazard ratio (HR) (95% confidence interval (CI)) for overall survival (OS) when comparing avapritinib to midostaurin is 0.44 (95% CI: 0.25-0.76), indicating avapritinib may improve survival in patients with advanced systemic mastocytosis.
  • The adjusted odds ratio (AOR) for overall response rate (ORR) for avapritinib versus midostaurin is 4.06 (95% CI: 3.09-5.33), suggesting a higher likelihood of treatment response with avapritinib.
  • The adjusted odds ratio for complete remission (CR) for avapritinib compared to midostaurin is 9.56 (95% CI: 0.97-93.81), showing potential improvement in achieving complete remission with avapritinib, though the wide confidence interval indicates variability in the estimate.
  • There is no safety information available in the reviewed studies.
  • There is no population types or subgroups information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Ayvakit (avapritinib) Prescribing Information.2023Blueprint Medicines Corporation., Cambridge, MA

Systematic Reviews / Meta-Analyses